HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...

Kenya has the seventh-largest number of people living with HIV in the world, at around 1.4 million, according to World Health ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...